AstraZeneca PLC has disclosed its total voting rights in a recent filing, revealing that as of October 31, 2026, the company has 1,551,065,237 ordinary shares with voting rights. This announcement is crucial for shareholders, as it informs them of the number of shares that can be used in determining their voting interests within the company.

The filing, submitted on November 2, 2026, under the SEC’s 6-K form, highlights AstraZeneca's commitment to transparency and compliance with regulatory requirements. The total number of voting rights is significant as it allows shareholders to understand their position and obligations under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Background

AstraZeneca PLC, traded on the NYSE under the ticker AZN, is a leading global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company specializes in various therapeutic areas, including oncology, rare diseases, and bio-pharmaceuticals. AstraZeneca is headquartered in Cambridge, UK, and operates in over 125 countries, providing innovative medicines to millions of patients worldwide.

What the Filing Says

The recent filing states, "As at 31 October 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,065,237 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,065,237." This information is vital for shareholders as it serves as the denominator for determining whether they need to notify changes in their interests in the company.

Impact

This disclosure affects AstraZeneca's shareholders, as it provides them with the necessary information to comply with the UK Financial Conduct Authority's regulations. The transparency in reporting voting rights enhances trust and accountability within the company and among its investors.

What's Next

The filing does not say what happens next.